Developer docs
API playgroundTry for free, no card

Search company profiles

Achaogen

Full company profile

uuid0005fcc

Namestring
Achaogen
Websiteurl
achaogen.com
Company typeenum
Private
Founded yearint
2004
Descriptiontext

Achaogen was a clinical-stage and subsequently commercial-stage biopharmaceutical company founded in 2004 and headquartered in South San Francisco, California. The company specialized in discovering and developing broad-spectrum antibiotics targeting multi-drug resistant Gram-negative bacterial infections, addressing the global antimicrobial resistance (AMR) crisis. Its lead asset, Zemdri (plazomicin), was an FDA-approved aminoglycoside antibiotic indicated for complicated urinary tract infections (cUTI) and bloodstream infections caused by resistant Gram-negative bacteria. The company's underlying technology focused on chemical modification of aminoglycoside scaffolds to circumvent common resistance mechanisms such as aminoglycoside-modifying enzymes.

The company's business model centered on specialty pharmaceutical commercialization of Zemdri to healthcare providers, primarily hospitals and infectious disease specialists treating serious resistant infections. Achaogen pursued a horizontal go-to-market approach with a single product franchise, supported by approximately 11-50 employees at peak operating scale. The company funded its operations through a combination of venture capital and government/non-dilutive sources, including multiple rounds from 5AM Ventures, ARCH Venture Partners, Frazier Healthcare Partners, Domain Associates, Venrock, Versant Ventures, Wellcome Trust, and CARB-X, with total disclosed funding exceeding $178 million across multiple rounds from 2004 through 2018. The company had been publicly traded on NASDAQ under the ticker AKAO.

Despite achieving FDA approval for Zemdri, Achaogen's commercial trajectory was untenable. The company generated only $8.73 million in gross revenue while sustaining a $186.51 million net loss, reflecting the well-documented market failure dynamic for new antibiotics where stewardship-driven volume constraints limit commercial return. Achaogen filed for Chapter 11 bankruptcy protection in April 2019 and completed liquidation in May 2020, formally ceasing all operations. Residual securities traded on OTC Markets under the ticker AKAOQ.

Short descriptiontext

Achaogen was a South San Francisco biopharmaceutical company that developed broad-spectrum antibiotics, including FDA-approved Zemdri (plazomicin), targeting multi-drug resistant Gram-negative bacterial infections in healthcare settings. The company filed for bankruptcy in 2019 and liquidated in 2020.

Operating statusenum
Closed
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersSouth San Francisco, United States
HQ citystring
South San Francisco
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Keyword5 values
antibiotic drug development, biopharmaceutical research, Gram-negative infections, aminoglycoside antibiotics, anti-infective therapeutics
Industry1 code
PRIMARYHLAIAAAG
Infectious Disease & Antimicrobials Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
NAICS code1 code
  • Pharmaceutical and Medicine Manufacturing3254
SIC code1 code
  • Biological Products, (No Disgnostic Substances)2836
Product category
Anti-infective Pharmaceuticals
Cost components5 values
Personnel, Technology or R&D, Marketing or Sales, Operations, Supply Chain
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Achaogen is a biopharmaceutical company that discovers and develops broad-spectrum antibiotics targeting multi-drug resistant Gram-negative bacterial infections. Its primary commercial product, Zemdri (plazomicin), is an aminoglycoside antibiotic indicated for complicated urinary tract infections (cUTI) and bloodstream infections caused by resistant bacteria.

Differentiator
Functional benefit
Problem solved
Product overview1 text field

Achaogen was a small-cap biotech company that filed for Chapter 11 bankruptcy in April 2019 and completed liquidation in May 2020. The company developed antibiotics, including Zemdri (plazomicin), an aminoglycoside antibiotic. Due to the company's liquidation and the limited source data available, detailed product portfolio information cannot be fully documented. The Zemdri domain (zemdri.com) currently redirects to a security verification page rather than active product information.

Product and service1 record
1Zemdri (plazomicin)
Scale indicator3 records

Each record includes

Type, Value, Description, Source

Recent move5 records

Each record includes

Date, Type, Title, Description, Source

Peers10 records
TypeDirect peer
Description

Tetraphase developed eravacycline, a tetracycline antibiotic targeting MDR infections including complicated intra-abdominal and urinary tract infections. It was a direct comparable to Achaogen in the small-cap hospital antibiotic space and ultimately followed a similar path, acquired by La Jolla Pharmaceutical Company in 2020 after commercial underperformance.

TypeDirect peer
Description

Melinta Therapeutics commercialized antibiotics including Baxdela (delafloxacin) and Orbactiv for MDR bacterial infections. Like Achaogen, it was a small-cap hospital antibiotic developer that filed for bankruptcy in 2019, illustrating the shared commercial challenge in this category.

TypeDirect peer
Description

Paratek developed and commercialized Nuzyra (omadacycline), a broad-spectrum antibiotic approved for community-acquired pneumonia and skin infections, including activity against MDR pathogens. It is a direct small-cap hospital antibiotic peer targeting similar prescribers and stewardship-constrained channels.

TypeDirect peer
Description

Spero Therapeutics developed antibiotics for MDR Gram-negative infections, including Tebipenem HBr for complicated urinary tract infections. It pursued a similar regulatory and commercialization strategy in the same hospital-treated MDR space as Achaogen.

TypeDirect peer
Description

Iterum Therapeutics developed sulopenem, an oral and IV antibiotic for uncomplicated and complicated urinary tract infections caused by MDR pathogens. It directly competed with Zemdri in the cUTI indication and shared Achaogen's small-cap, single-asset risk profile.

TypeDirect peer
Description

Entasis Therapeutics was a small-cap biotech developing targeted antibacterial therapies for MDR Gram-negative infections, including Xerava (eravacycline) and durlobactam. It operated in the same narrow therapeutic niche as Achaogen.

TypeBroad incumbent
Description

Shionogi licensed ex-US rights to Zemdri from Achaogen and is a broader Japanese pharmaceutical incumbent with deep antibiotic development capabilities. It is comparable as the global commercial partner and a major player in the same anti-infective category.

TypeBroad incumbent
Description

Merck is a broad incumbent pharmaceutical company with a significant anti-infective portfolio (e.g., Zerbaxa, Recarbrio). It overlaps with Achaogen in the hospital antibiotic market but operates at a vastly larger scale and across multiple therapeutic areas.

TypeBroad incumbent
Description

Pfizer maintains a broad anti-infective franchise (including Zavicefta and other beta-lactam/beta-lactamase inhibitors) targeting MDR Gram-negative infections. It is a broad incumbent competing in the same hospital prescriber channels as Achaogen.

TypeEmerging player
Description

VenatoRx develops antibiotics targeting MDR Gram-negative infections, including cefepime-taniborbactam. It is an emerging private peer operating in the same narrow therapeutic space that Achaogen once led.

Market position
Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat2 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights5 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment1 record

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles6 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds8 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors10 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Achaogen

Anti-infective Pharmaceuticalsachaogen.com

Achaogen was a South San Francisco biopharmaceutical company that developed broad-spectrum antibiotics, including FDA-approved Zemdri (plazomicin), targeting multi-drug resistant Gram-negative bacterial infections in healthcare settings. The company filed for bankruptcy in 2019 and liquidated in 2020.

What Achaogen does

Achaogen was a clinical-stage and subsequently commercial-stage biopharmaceutical company founded in 2004 and headquartered in South San Francisco, California. The company specialized in discovering and developing broad-spectrum antibiotics targeting multi-drug resistant Gram-negative bacterial infections, addressing the global antimicrobial resistance (AMR) crisis. Its lead asset, Zemdri (plazomicin), was an FDA-approved aminoglycoside antibiotic indicated for complicated urinary tract infections (cUTI) and bloodstream infections caused by resistant Gram-negative bacteria. The company's underlying technology focused on chemical modification of aminoglycoside scaffolds to circumvent common resistance mechanisms such as aminoglycoside-modifying enzymes.

The company's business model centered on specialty pharmaceutical commercialization of Zemdri to healthcare providers, primarily hospitals and infectious disease specialists treating serious resistant infections. Achaogen pursued a horizontal go-to-market approach with a single product franchise, supported by approximately 11-50 employees at peak operating scale. The company funded its operations through a combination of venture capital and government/non-dilutive sources, including multiple rounds from 5AM Ventures, ARCH Venture Partners, Frazier Healthcare Partners, Domain Associates, Venrock, Versant Ventures, Wellcome Trust, and CARB-X, with total disclosed funding exceeding $178 million across multiple rounds from 2004 through 2018. The company had been publicly traded on NASDAQ under the ticker AKAO.

Despite achieving FDA approval for Zemdri, Achaogen's commercial trajectory was untenable. The company generated only $8.73 million in gross revenue while sustaining a $186.51 million net loss, reflecting the well-documented market failure dynamic for new antibiotics where stewardship-driven volume constraints limit commercial return. Achaogen filed for Chapter 11 bankruptcy protection in April 2019 and completed liquidation in May 2020, formally ceasing all operations. Residual securities traded on OTC Markets under the ticker AKAOQ.

Achaogen firmographics

Firmographics
Name
Achaogen
Website
https://achaogen.com
Company type
Private
Founded year
2004
Operating status
Closed
Headcount range
11–50 employees
Short description
Achaogen was a South San Francisco biopharmaceutical company that developed broad-spectrum antibiotics, including FDA-approved Zemdri (plazomicin), targeting multi-drug resistant Gram-negative bacterial infections in healthcare settings. The company filed for bankruptcy in 2019 and liquidated in 2020.
Ownership category
akta.pro rank

Achaogen industry classification

Industry
Product category
Anti-infective Pharmaceuticals
NAICS
Pharmaceutical and Medicine Manufacturing (3254)
SIC
Biological Products, (No Disgnostic Substances) (2836)
akta.pro industry
PRIMARYHLAIAAAG
Infectious Disease & Antimicrobials Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals

Keywords

  • Antibiotic drug development
  • Biopharmaceutical research
  • Gram-negative infections
  • Aminoglycoside antibiotics
  • Anti-infective therapeutics

Where Achaogen is headquartered

Location

Headquarters

HQ city
South San Francisco
HQ country
United States
HQ region
North America

Markets served

Achaogen business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Personnel, Technology or R&D, Marketing or Sales, Operations, Supply Chain

Achaogen product offering

Product offering

Core offering

Achaogen is a biopharmaceutical company that discovers and develops broad-spectrum antibiotics targeting multi-drug resistant Gram-negative bacterial infections. Its primary commercial product, Zemdri (plazomicin), is an aminoglycoside antibiotic indicated for complicated urinary tract infections (cUTI) and bloodstream infections caused by resistant bacteria.

Product overview

Achaogen was a small-cap biotech company that filed for Chapter 11 bankruptcy in April 2019 and completed liquidation in May 2020. The company developed antibiotics, including Zemdri (plazomicin), an aminoglycoside antibiotic. Due to the company's liquidation and the limited source data available, detailed product portfolio information cannot be fully documented. The Zemdri domain (zemdri.com) currently redirects to a security verification page rather than active product information.

Differentiator

Problem solved

Functional benefit

Products and services

  • Zemdri (plazomicin)

Companies that use Achaogen

Customer profile

Segments1 record

Ideal customer profiles1 record

Achaogen technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Achaogen partnerships and signals

Strategic signal

Scale indicators3 records

Recent moves5 records

Achaogen competitors and assessment

Company assessment

Direct peers

  • Tetraphase Pharmaceuticals: Tetraphase developed eravacycline, a tetracycline antibiotic targeting MDR infections including complicated intra-abdominal and urinary tract infections. It was a direct comparable to Achaogen in the small-cap hospital antibiotic space and ultimately followed a similar path, acquired by La Jolla Pharmaceutical Company in 2020 after commercial underperformance.
  • Melinta Therapeutics: Melinta Therapeutics commercialized antibiotics including Baxdela (delafloxacin) and Orbactiv for MDR bacterial infections. Like Achaogen, it was a small-cap hospital antibiotic developer that filed for bankruptcy in 2019, illustrating the shared commercial challenge in this category.
  • Paratek Pharmaceuticals: Paratek developed and commercialized Nuzyra (omadacycline), a broad-spectrum antibiotic approved for community-acquired pneumonia and skin infections, including activity against MDR pathogens. It is a direct small-cap hospital antibiotic peer targeting similar prescribers and stewardship-constrained channels.
  • Spero Therapeutics: Spero Therapeutics developed antibiotics for MDR Gram-negative infections, including Tebipenem HBr for complicated urinary tract infections. It pursued a similar regulatory and commercialization strategy in the same hospital-treated MDR space as Achaogen.
  • Iterum Therapeutics: Iterum Therapeutics developed sulopenem, an oral and IV antibiotic for uncomplicated and complicated urinary tract infections caused by MDR pathogens. It directly competed with Zemdri in the cUTI indication and shared Achaogen's small-cap, single-asset risk profile.
  • Entasis Therapeutics: Entasis Therapeutics was a small-cap biotech developing targeted antibacterial therapies for MDR Gram-negative infections, including Xerava (eravacycline) and durlobactam. It operated in the same narrow therapeutic niche as Achaogen.

Broad incumbents

  • Shionogi: Shionogi licensed ex-US rights to Zemdri from Achaogen and is a broader Japanese pharmaceutical incumbent with deep antibiotic development capabilities. It is comparable as the global commercial partner and a major player in the same anti-infective category.
  • Merck & Co. Merck is a broad incumbent pharmaceutical company with a significant anti-infective portfolio (e.g., Zerbaxa, Recarbrio). It overlaps with Achaogen in the hospital antibiotic market but operates at a vastly larger scale and across multiple therapeutic areas.
  • Pfizer: Pfizer maintains a broad anti-infective franchise (including Zavicefta and other beta-lactam/beta-lactamase inhibitors) targeting MDR Gram-negative infections. It is a broad incumbent competing in the same hospital prescriber channels as Achaogen.

Emerging players

  • VenatoRx Pharmaceuticals: VenatoRx develops antibiotics targeting MDR Gram-negative infections, including cefepime-taniborbactam. It is an emerging private peer operating in the same narrow therapeutic space that Achaogen once led.

Market position

Weaknesses5 records

Competitive moat2 records

Key risks6 records

Key highlights5 records

Customer concentration

Achaogen social profiles

Digital presence

Achaogen financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Achaogen leadership team

Management profile

Number of profiles

Profiles6 records

Achaogen funding detail

Funding detail

Funding overview

Funding rounds8 records

Investors10 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Achaogen M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Achaogen

What does Achaogen do?

Achaogen is a biopharmaceutical company that discovers and develops broad-spectrum antibiotics targeting multi-drug resistant Gram-negative bacterial infections. Its primary commercial product, Zemdri (plazomicin), is an aminoglycoside antibiotic indicated for complicated urinary tract infections (cUTI) and bloodstream infections caused by resistant bacteria.

Is Achaogen a public or private company?

Achaogen is a private company. It is classified as public and is currently closed.

When was Achaogen founded?

Achaogen was founded in 2004. It employs 11 to 50 people.

Where is Achaogen based?

Achaogen is headquartered in South San Francisco, United States, in the North America region.

Who are Achaogen's main competitors?

Direct peers on record are Tetraphase Pharmaceuticals, Melinta Therapeutics, Paratek Pharmaceuticals, Spero Therapeutics, Iterum Therapeutics and Entasis Therapeutics. Broad incumbents are Shionogi, Merck & Co. and Pfizer. VenatoRx Pharmaceuticals is listed as an emerging player.

Does Achaogen have an API?

No public API is recorded for Achaogen.

What industry is Achaogen in?

Achaogen's product category is Anti-infective Pharmaceuticals. Its primary akta.pro industry code is HLAIAAAG, Infectious Disease & Antimicrobials Pharmaceuticals. Its NAICS code is 3254 and its SIC code is 2836.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Defense WorldReviewing iBio (NASDAQ:IBIO) & Achaogen (OTCMKTS:AKAOQ)This article compares two small-cap biotech manufacturing companies, iBio and Achaogen, across twelve financial metrics including analyst ratings, profitability, earnings, valuation, and volatility. iBio scored favorably on eight of twelve comparison factors, with a consensus target price of $4.75 indicating 169.89% potential upside, while Achaogen carries no analyst ratings. iBio generated $400,000 in gross revenue versus Achaogen's $8.73 million, though iBio posted a smaller net loss of $18.38 million compared to Achaogen's $186.51 million loss. The article notes Achaogen filed for Chapter 11 bankruptcy in April 2019 and completed liquidation in May 2020.NatureNovel insights from financial analysis of the failure to commercialise plazomicin: Implications for the antibiotic investment ecosystemFinancial analysis of Achaogen's 2004–2019 development and failed commercialization of plazomicin reveals the company raised $770 million (71% from capital markets, 26% public grants, 3% philanthropy) yet filed for bankruptcy in April 2019, less than a year after FDA approval, generating only $0.8 million in plazomicin sales against over $60 million annual cash burn. Post-bankruptcy, worldwide rights were acquired by Cipla for $4.65 million and Greater China rights by Sihuan Pharmaceutical for $4.5 million, yet neither has successfully commercialized the drug, leaving a WHO-listed antibiotic inaccessible despite its clinical potential against drug-resistant infections.FortuneAntibiotic Industry: How to Fix Its InfectionAchaogen, a biotech that developed an FDA-approved antibiotic, sold its assets for $16 million after filing for Chapter 11 bankruptcy. The article argues that low volumes and low price points under DRG reimbursement make antibiotic development commercially untenable. It proposes the DISARM Act and REVAMP Act to fix these incentives.GlobeNewswireAchaogen, Inc. Announces Results of Auction for Substantially All Company AssetsAchaogen, Inc. announced agreements to sell substantially all its assets for approximately $16 million in cash, plus royalties and liability assumption. The sale involves Cipla USA, QiLu Antibiotics, and Heritage Global Partners, with binding documents expected by June 14, 2019.WIREDThe Radical Plan to Change How Antibiotics Get DevelopedLeading thinkers are proposing to remove profit from antibiotic R&D, suggesting government or nonprofit entities take over. The Achaogen bankruptcy and over $600 million in wasted funding have fueled these ideas. The goal is a new paradigm to guarantee antibiotic production for decades.MedCity NewsNew antibiotics are urgently needed, but economics stand in the wayAchaogen filed for Chapter 11 bankruptcy in April 2019 after its antibiotic Zemdri generated only $783,000 in sales against over $189 million in operating losses. The article argues that antibiotics lack high-value pricing and reimbursement, making development unprofitable despite urgent clinical need.WIREDThe Antibiotics Business Is Broken—But There's a FixAchaogen, an antibiotics company, filed for bankruptcy after its drug Zemdri earned less than $1 million, highlighting broken financial structures. The article argues that pull incentives such as market entry rewards could fix the market, though they are expensive and politically difficult.PR NewswireInfection Control Seizes Headlines as Companies Look to Tackle Food-Borne IllnessesThe global infection control market, valued at USD 150.4 billion in 2016 and projected to grow at a 6.2% CAGR through 2025, is being driven by rising government initiatives and food safety concerns affecting an estimated 48 million annual cases of foodborne illness in the U.S. PCT Ltd. announced a repeat order for two large-volume Hydrolyte Systems from an existing food processing customer, citing the company's quality equipment and reliability as factors in the repeat purchase. The article also covers unrelated strategic updates from four other companies: Conagra Brands exploring strategic alternatives for its Gelit frozen pasta business, Flowers Foods completing its acquisition of Canyon Bakehouse LLC, CorMedix receiving a positive DSMB recommendation to terminate its Phase 3 LOCK-IT-100 study early for Neutrolin, and Achaogen submitting a Marketing Authorization Application to the EMA for plazomicin.PR NewswireTechnological Advancements Show Growth in the Hospital Acquired Infection Control MarketThe Hospital Acquired Infection Control Market is projected to reach USD 33.78 billion by 2021, growing at a CAGR of 8.3%, driven by increased demand for infection control measures in healthcare facilities. Multiple companies announced corporate developments including PCT LTD's full-scale marketing launch of its Annihilyzer Infection Control Systems following successful beta trials, Rigel Pharmaceuticals' exclusive licensing agreement with Kissei Pharmaceutical for TAVALISSE in Asian markets, Achaogen's Marketing Authorization Application submission to the European Medicines Agency for plazomicin, and SCYNEXIS receiving FDA QIDP and Fast Track designations for oral SCY-078.